SCHEMBL7222525

SCHEMBL7222525

O=C1NCC(c2ccc(C(=O)O)cc2)CN1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.44
TP53 P04637 1/20 0.44
SRD5A2 P31213 2/20 0.40
CA1 P00915 4/20 0.39
CA12 O43570 3/20 0.39
CA9 Q16790 3/20 0.39
CA2 P00918 3/20 0.39
CA3 P07451 1/20 0.39
TYR P14679 1/20 0.39
DRD1 P21728 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
NAPRT Q6XQN6 2/20 0.38
ALOX15 P16050 1/20 0.38
METAP1 P53582 1/20 0.38
TPMT P51580 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15984732 0.82 TSHR (0.50) TSHRTP53SRD5A2CA1CA12
SCHEMBL7233581 0.80 HTT (0.52) TSHRTP53CA1CA12CA9
SCHEMBL7222002 0.80 DDB1 (0.46) TSHRTP53SRD5A2CA1CA12
SCHEMBL31718053 0.76 TSHR (0.57) TSHRTP53SRD5A2CA1CA12
SCHEMBL2321634 0.76 TSHR (0.57) TSHRTP53SRD5A2CA1CA12
SCHEMBL901207 0.76 TSHR (0.57) TSHRTP53SRD5A2CA1CA12
SCHEMBL901209 0.76 TSHR (0.57) TSHRTP53SRD5A2CA1CA12
Hydrochloric Acid SCHEMBL4290507 0.74 TSHR (0.55) TSHRTP53SRD5A2CA1CA12
SCHEMBL31386222 0.73 JAK3 (0.59)
SCHEMBL3495930 0.72 HDAC8 (0.63) TSHRTP53SRD5A2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US disclosed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds SERPINC1, F2, F11 TSHR 2219/4885TP53 4675/4885SRD5A2 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.